Technology
Health
Biotechnology

Infinity Pharmaceuticals

$1.80
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

$0.00 (0.00%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell INFI and other stocks, options, ETFs, and crypto commission-free!

About

Infinity Pharmaceuticals, Inc. operates as a biopharmaceutical company, which engages in discovering, developing and delivering medicines for people with cancer. It focuses on drug development. Read More The company was founded by Steven H. Holtzman on March 22, 1995 and is headquartered in Cambridge, MA.

Employees
25
Headquarters
Cambridge, Massachusetts
Founded
1995
Market Cap
102.34M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
477.83K
High Today
$1.86
Low Today
$1.77
Open Price
$1.81
Volume
43.38K
52 Week High
$2.92
52 Week Low
$1.00

Collections

Technology
Health
Biotechnology
Biopharmaceutical
Cancer Prevention
Pharmaceutical
US
North America

News

Yahoo FinanceMar 15

Infinity Inks Deal With Roche for Phase II Study of IPI-549

Shares of Infinity Pharmaceuticals Inc. INFI rose almost 24% after the company announced that it has entered into a master clinical supply agreement with Roche RHHBY. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity for use in MARIO-3, a phase II multi-arm combination cohort study. The study will evaluate Infinity’s lead immuno-oncology candidate, IPI-549in combination with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple negative breast cancer (TNBC), and IPI-549 in combinat...

82
Seeking AlphaMar 14

Infinity Pharmaceuticals beats by $0.03, revenue in-line - Infinity Pharmaceuticals, Inc. (NASDAQ:INFI)

184
Markets InsiderMar 14

Infinity Pharmaceuticals Reports Full Year 2018 Financial Results and Provides Company Update

CAMBRIDGE, Mass., March 14, 2019 /PRNewswire/ -- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced its full year 2018 financial results and provided an update on the company, including its progress with IPI-549, a first-in-class oral immuno-oncology product candidate targeting immune-suppressive tumor-associated myeloid cells through selective phosphoinositide-3-kinase-gamma (PI3K-gamma) inhibition. Today, Infinity also announced MARIO-3, a Phase 2 study in collaboration with Roche, which will e...

30

Earnings

-$0.34
-$0.15
$0.04
$0.23
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.17 per share
Actual
-$0.14 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.